Close

Aeglea BioTherapeutics (AGLE) Says Data Shows AEB3103 Suppresses Cancer Growth in Preclinical Models

November 21, 2016 11:04 AM EST Send to a Friend
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login